HK1091199A1 - Quinazoline derivatives and use thereof in the manufacture of medicaments - Google Patents

Quinazoline derivatives and use thereof in the manufacture of medicaments

Info

Publication number
HK1091199A1
HK1091199A1 HK06111733.3A HK06111733A HK1091199A1 HK 1091199 A1 HK1091199 A1 HK 1091199A1 HK 06111733 A HK06111733 A HK 06111733A HK 1091199 A1 HK1091199 A1 HK 1091199A1
Authority
HK
Hong Kong
Prior art keywords
medicaments
manufacture
quinazoline derivatives
quinazoline
derivatives
Prior art date
Application number
HK06111733.3A
Other languages
English (en)
Inventor
Yoshinori Sekiguchi
Kosuke Kanuma
Katsunori Omodera
Tsuyoshi Busujima
Thuy-Anh Tran
Sangdon S Han
Martin Casper
Bryan A Kramer
Original Assignee
Taisho Pharmaceutical Co Ltd
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd, Arena Pharm Inc filed Critical Taisho Pharmaceutical Co Ltd
Publication of HK1091199A1 publication Critical patent/HK1091199A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK06111733.3A 2003-03-31 2006-10-24 Quinazoline derivatives and use thereof in the manufacture of medicaments HK1091199A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45842403P 2003-03-31 2003-03-31
PCT/JP2004/004554 WO2004087680A1 (en) 2003-03-31 2004-03-30 Novel quinazoline derivatives and methods of treatment related to the use thereof

Publications (1)

Publication Number Publication Date
HK1091199A1 true HK1091199A1 (en) 2007-01-12

Family

ID=33131792

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06111733.3A HK1091199A1 (en) 2003-03-31 2006-10-24 Quinazoline derivatives and use thereof in the manufacture of medicaments

Country Status (6)

Country Link
US (1) US20070010671A1 (xx)
EP (1) EP1611109A4 (xx)
JP (1) JP2006522109A (xx)
CN (1) CN100475793C (xx)
HK (1) HK1091199A1 (xx)
WO (1) WO2004087680A1 (xx)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004315511A (ja) * 2003-03-31 2004-11-11 Taisho Pharmaceut Co Ltd Ｍｃｈ受容体アンタゴニスト
GB0400193D0 (en) * 2004-01-07 2004-02-11 Astrazeneca Ab Therapeutic agents
US7230002B2 (en) 2004-02-03 2007-06-12 Glenmark Pharmaceuticals Ltd. Dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof
WO2005075426A1 (en) * 2004-02-03 2005-08-18 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
CN1976905A (zh) * 2004-03-30 2007-06-06 大正制药株式会社 嘧啶衍生物以及与其应用有关的治疗方法
WO2006011035A1 (en) * 2004-07-23 2006-02-02 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; process for their preparation and compositions containing them
FR2874014B1 (fr) * 2004-08-03 2010-05-14 Univ Paris Descartes Analogues d'aminoglycosides, leur utilisation et leur synthese
JP4959569B2 (ja) * 2004-10-12 2012-06-27 グレンマーク・ファーマシューティカルズ・エスエー 新規なジペプチジルペプチダーゼｉｖ阻害剤、それらを含む医薬品組成物、およびそれらを調製するためのプロセス
EP1844023A1 (en) * 2004-12-31 2007-10-17 Sk Chemicals Co., Ltd. Quinazoline derivatives for the treatment and prevention of diabetes and obesity
AU2006243244A1 (en) 2005-05-04 2006-11-09 F. Hoffmann-La Roche Ag (3,4-dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amines having an activity on the 5-HT receptor
JP2007091649A (ja) * 2005-09-29 2007-04-12 Taisho Pharmaceut Co Ltd ピリミジン誘導体及びその使用に関連する治療方法
US20090298834A1 (en) * 2008-06-02 2009-12-03 Hassan Pajouhesh 4-(aminomethyl)cyclohexanamine derivatives as calcium channel blockers
UA105187C2 (xx) * 2008-10-02 2014-04-25 Таісо Фармас'Ютікел Ко., Лтд. Похідне 7-піперидиналкіл-3,4-дигідрохінолону$производное 7- пиперидиналкил-3, 4-дигидрохинолона
CN102264228A (zh) 2008-10-22 2011-11-30 默沙东公司 用于抗糖尿病药的新的环状苯并咪唑衍生物
AU2009309037A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2404896A1 (en) * 2009-03-05 2012-01-11 Shionogi&Co., Ltd. Cyclohexane derivative having npy y5 receptor antagonism
CN102753535B (zh) 2009-09-03 2015-03-25 百时美施贵宝公司 作为钾离子通道抑制剂的喹唑啉
NZ600008A (en) 2009-12-04 2014-10-31 Sunovion Pharmaceuticals Inc Multicyclic compounds and methods of use thereof
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
ES2652662T3 (es) 2011-02-25 2018-02-05 Merck Sharp & Dohme Corp. Novedosos derivados de azabencimidazol cíclicos útiles como agentes antidiabéticos
AU2013296470B2 (en) 2012-08-02 2016-03-17 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
MX2015010935A (es) 2013-02-22 2015-10-29 Merck Sharp & Dohme Compuestos biciclicos antidiabeticos.
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN103739596A (zh) * 2013-12-10 2014-04-23 刘磊 用于心脑血管疾病的喹唑啉衍生物
EP3162366A4 (en) * 2014-06-27 2018-02-14 Ajinomoto Co., Inc. Sweetness receptor antagonist
PL3438096T3 (pl) * 2016-04-01 2021-05-17 Impact Therapeutics, Inc Sposób wytwarzania 1-(arylometylo)chinazolino-2,4(1H,3H)-dionu
US10196403B2 (en) 2016-07-29 2019-02-05 Sunovion Pharmaceuticals Inc. Compounds and compositions and uses thereof
BR112019001407A2 (pt) 2016-07-29 2019-07-09 Pgi Drug Discovery Llc compostos e composições e usos dos mesmos
KR20180025700A (ko) * 2016-09-01 2018-03-09 (주)아모레퍼시픽 2,4-디클로로-a-(3,4-디하이드로-4-옥소-2(1H)-퀴나졸리닐리덴)-β-옥소-벤젠프로판니트릴을 포함하는 멜라닌 증진용 조성물
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
CA3053903A1 (en) 2017-02-16 2018-08-23 Sunovion Pharmaceuticals Inc. Methods of treating schizophrenia
JP7191085B2 (ja) 2017-08-02 2022-12-16 サノビオン ファーマシューティカルズ インク イソクロマン化合物およびその使用
JP7453148B2 (ja) 2018-02-16 2024-03-19 サノビオン ファーマシューティカルズ インク 塩、結晶形態、およびその製造方法
JP2022525169A (ja) 2019-03-14 2022-05-11 サノビオン ファーマシューティカルズ インク イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物
BR112021014881A2 (pt) * 2019-06-12 2022-02-15 Univ East China Science & Tech Composto de poliol anti-hipertensivo e derivados do mesmo
CN110204555A (zh) * 2019-07-10 2019-09-06 河南龙湖生物技术有限公司 具有聚氯乙烯光稳定作用的三嗪类化合物的制备方法和应用
KR20220066252A (ko) 2019-07-11 2022-05-24 프락시스 프리시젼 메디신즈, 인크. T형 칼슘 채널 조절제의 제형 및 이의 사용 방법
CN115734785A (zh) 2020-04-14 2023-03-03 桑诺维恩药品公司 (S)-(4,5-二氢-7H-噻吩并[2,3-c]吡喃-7-基)-N-甲基甲胺用于治疗神经和精神方面的病症

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020823A2 (en) * 1995-12-01 1997-06-12 Novartis Ag 2-amino quinazoline derivatives as npy receptor antagonists
AU7626496A (en) * 1995-12-01 1997-06-27 Ciba-Geigy Ag Heteroaryl compounds
AU7692896A (en) * 1995-12-01 1997-06-27 Novartis Ag Quinazolin-2,4-diazirines as NPY receptor antagonist
US5874438A (en) * 1996-10-11 1999-02-23 Bayer Aktiengesellschaft 2,2'-bridged bis-2,4-diaminoquinazolines
CN1582281A (zh) * 2001-10-01 2005-02-16 大正制药株式会社 Mch受体拮抗剂

Also Published As

Publication number Publication date
US20070010671A1 (en) 2007-01-11
WO2004087680A1 (en) 2004-10-14
CN100475793C (zh) 2009-04-08
EP1611109A4 (en) 2009-06-24
EP1611109A1 (en) 2006-01-04
CN1795180A (zh) 2006-06-28
JP2006522109A (ja) 2006-09-28

Similar Documents

Publication Publication Date Title
HK1091199A1 (en) Quinazoline derivatives and use thereof in the manufacture of medicaments
IL231576A (en) Derivatives of adamantyl-acetamide, the pharmaceutical compositions containing them and their use in the preparation of medicines
HK1080481A1 (en) Phosphonooxy quinazoline derivatives and their pharmaceutical use
IL213597A0 (en) Compounds, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
HK1078086A1 (zh) 雜芳族五環化合物及其醫藥用途
IL187528A0 (en) Use of pyrimidine compounds in the manufacture of medicaments
IL210785A0 (en) Quinazoline derivatives and their use in the manufacture of medicaments for inhibiting angiogenesis or reducing vascular permeability
TWI349551B (en) Thiophenepyrimidinone derivatives and their use in therapy
IL183583A0 (en) Quinazoline derivatives and pharmaceutical compositions containing the same
EP1367060A4 (en) GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND THEIR MEDICAL USE
EP1364957A4 (en) GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND THEIR MEDICAL USE
HK1084883A1 (en) 2-cyanopyrrolopyrimidines and pharmaceutical uses thereof
HK1164133A1 (en) Nasal pharmaceutical formulations and methods of using the same
HK1097256A1 (en) Pyrizdazine derivatives and their use as therapeutic agents
AU2003252478A1 (en) Ccr4 antagonist and medicinal use thereof
HK1091727A1 (en) Nasal pharmaceutical formulations and methods of using the same
IL164463A0 (en) Use of osteoprotegerin in the preparation of medicaments
EP1469860A4 (en) ANTICANCER COMBINATION AND USE THEREOF
IL184008A0 (en) 4-cycloalkyl-substituted tetrahydrochinoline derivatives and use thereof as medicaments
HK1081864A1 (en) Anti-inflammatory compositions and use of the same in the manufacture of medicaments
AU2002343103A1 (en) Aminoalkylimidazole derivatives and their use in medicine
AU2003244455A1 (en) Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
HUP0303612A3 (en) Bicyclic guanidine derivatives and their therapeutic use
EP1666046A4 (en) USE OF N-ACETYL-D-AMINOGLYCOSAMINE FOR THE PREPARATION OF DRUGS FOR THE TREATMENT OF CANCER AND METASTASES
EE200300466A (et) Püridoindolooni derivaatide kasutamine ravimite valmistamiseks

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130330